

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	0	("immunomodulatedexendin").PN.	US-PGPUB; USPAT	OR	OFF	2005/10/18 15:41
L3	0	("immunomodulatedexendin").PN.	US-PGPUB; USPAT	OR	OFF	2005/10/18 15:41
L4	1	immunomodulated exendin	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:41
L5	64910	"1" with immuno\$	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:42
L6	355	exendin-4	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:42
L7	18	6 with immuno\$	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:42
S1	355	exendin-4	US-PGPUB; USPAT	ADJ	ON	2005/10/18 15:13
S2	3014	thiazolidinedione	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:06
S3	3	S1 same S2 same diabetes	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:10
S4	249	diabetes related disease	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:10
S5	1	S1 same S2 same S4	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:54
S6	3302	troglitazone or ciglitazone or pioglitazone or rosiglitazone or isaglitazone or darglitazone or englitazone	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:54
S7	54	S1 same S6	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:54
S8	23	S7 same diabetes	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:55
S9	23	S8 not S3	US-PGPUB; USPAT	ADJ	ON	2005/10/18 13:55
S10	1	("20030087820").PN.	US-PGPUB; USPAT	OR	OFF	2005/10/18 15:40

\$*STN;HighlightOn= +;;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653raw

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03 MATHDI removed from STN
NEWS 9 OCT 04 CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added
to core patent offices.
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPLUS documents for use in third-party analysis and
visualization tools

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:45:37 ON 18 OCT 2005

=> index biosci

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:45:58 ON 18 OCT

2005

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> index biosci -uspatfull -uspat2
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.59	0.80

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:46:13 ON 18 OCT

2005

72 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s exerdin (p) thiazolidinedione

1 FILE ADISINSIGHT

0* FILE ADISNEWS

0* FILE ANTE

0* FILE AQUALINE

0* FILE BIOCOMMERCE

0* FILE BIOENG

1* FILE BIOTECHABS

1* FILE BIOTECHDS

1* FILE BIOTECHNO

2 FILE CAPLUS

0* FILE CEABA-VTB

0* FILE CIN

196 FILE DGENE

1 FILE DRUGU

31 FILES SEARCHED...

0* FILE ESIIOBASE

0* FILE FEDRIP

0* FILE FONAD

0* FILE FOREG

0* FILE FROSTI

0* FILE FSTA

4 FILE IFIPAT

0* FILE KOSMET
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
1 FILE TOXCENTER
0* FILE WATER
4 FILE WPIDS
4 FILE WPINDEX

11 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STINDEX

L1 QUE EXENDIN (P) THIAZOLIDINEDIONE

=> s 11 (p) diabetes

1 FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
0* FILE BIOCOMMERCE
0* FILE BIOENG
1* FILE BIOTECHABS
1* FILE BIOTECHDS
1* FILE BIOTECHNO
2 FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN
196 FILE DGENE
1 FILE DRUGU
0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
4 FILE IFIPAT
0* FILE KOSMET
0* FILE NTIS
51 FILES SEARCHED...
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
0* FILE WATER
4 FILE WPIDS
4 FILE WPINDEX

10 FILES HAVE ONE OR MORE ANSWERS, 72 FILES SEARCHED IN STINDEX

L2 QUE L1 (P) DIABETES

=> file hits

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.54	4.34

FILE 'DGENE' ENTERED AT 15:49:53 ON 18 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'IFIPAT' ENTERED AT 15:49:53 ON 18 OCT 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'WPIDS' ENTERED AT 15:49:53 ON 18 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'CAPLUS' ENTERED AT 15:49:53 ON 18 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ADISINSIGHT' ENTERED AT 15:49:53 ON 18 OCT 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'DRUGU' ENTERED AT 15:49:53 ON 18 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:49:53 ON 18 OCT 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 15:49:53 ON 18 OCT 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s 12
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN (P) THIAZOLID'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) DIABETES'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'EXENDIN (P) THIAZOLID'
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (P) DIABETES'
L3 210 L2

=> dup rem L3
DUPLICATE IS NOT AVAILABLE IN 'DGENE, ADISINSIGHT'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4 208 DUP REM L3 (2 DUPLICATES REMOVED)

=> s 14 and synerg?
L5 4 L4 AND SYNERG?

=> d 15 bib ab 1-4

L5 ANSWER 1 OF 4 IFIPAT COPYRIGHT 2005 IFI on STN
AN 10673585 IFIPAT;IFIUDB;IFICDB
T1 COMBINATION TREATMENT USING EXENDINS AND THIAZOLIDINEDIONES
INF Knudsen; Lotte Bjerre, Kalundborg, DK
IN Knudsen Lotte Bjerre (DK)
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)

PPA Novo Nordisk A/S DK (Probable)
AG NOVO NORDISK PHARMACEUTICALS, INC, 100 COLLEGE ROAD WEST, PRINCETON, NJ, 08540, US

PI US 2004180824 A1 20040916
AI US 2003-726734 20031203
PRAI DK 2002-1864 20021203
US 2002-431999P (Provisional)
FI US 2004180824 20040916
DT Utility; Patent Application - First Publication
FS CHEMICAL

PARN This application claims priority under 35 U.S.C. 119 of Danish application no. PA 2002 01864 filed Dec. 3, 2002 and U.S. application No. 60/431999 filed Dec. 9, 2002, the contents of which are fully incorporated herein by reference.

CLAIM 71
OF 4 IFIPAT COPYRIGHT 2005 IFI on STN

AB The present invention relates to methods for treatment and/or prevention of "...diabetes..." and "...diabetes..." related diseases. More specifically, the methods and uses of the invention pertain to administration of an "...exendin..." -4 compound in combination with administration of a "...thiazolidinedione..." insulin sensitizer.

L5 ANSWER 2 OF 4 IFIPAT COPYRIGHT 2005 IFI on STN

AN 10046926 IFIPAT;IFIUDB;IFICDB
TI EXENDIN DERIVATIVES; HAVING ONE LIPOPHILIC SUBSTITUENT WHICH IS ATTACHED TO THE C-TERMINAL AMINO ACID; TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS

INF Huusfeldt; Per Olaf, Copenhagen K, DK
Knudsen; Liselotte Bjerre, Valby, DK
Madsen; Kjeld, Værløse, DK
Nielsen; Per Franklyn, Værløse, DK
Huusfeldt Per Olaf (DK); Knudsen Liselotte Bjerre (DK); Madsen Kjeld (DK); Nielsen Per Franklyn (DK)

IN Unassigned
PAF Unassigned Or Assigned To Individual (680000)
PPA Novo Nordisk of North America Inc (Probable)
AG Reza Green, Esq. Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401, US

PI US 2001047084 A1 20011129
AI US 2001-896311 20010621
RLI WO 1999-DK86 19990224 CONTINUATION
US 1999-312177 19990514 CONTINUATION
DK 1998-274 19980227

PRAI US 1998-84357P 19980505 (Provisional)
FI US 2001047084 20011129
DT Utility; Patent Application - First Publication
FS CHEMICAL

CLAIM 91
AB The present invention relates to a derivative of GLP-1 (7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.

L5 ANSWER 3 OF 4 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2004-480530 [45] WPIDS
DNC C2004-178703

T1 Treating or preventing "...diabetes..." or "...diabetes..." -related disease by administering "...exendin..." -4 compound and "...thiazolidinedione..." insulin sensitizer to patient.

DC A96 B04 D16
IN KNUDSEN, L B
PA (KNUD-I) KNUDSEN L B; (NOVO) NOVO NORDISK AS
CYC 108
PI WO 2004050115 A2 20040617 (200445)* EN 31
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW NZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM GR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MN MW MX MY NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SH SI SJ SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

US 2004180824 A1 20040916 (200461)
AU 2003283216 A1 20040623 (200472)
EP 1569682 A2 20050907 (200559) EN
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR

ADT WO 2004050115 A2 WO 2003-DK824 20031201; US 2004180824 A1 Provisional US 2002-431999P 20021209, US 2003-726734 20031203; AU 2003283216 A1 AU 2003-283216 20031201; EP 1569682 A2 EP 2003-775117 20031201, WO 2003-DK824 20031201

FDT AU 2003283216 A1 Based on WO 2004050115; EP 1569682 A2 Based on WO 2004050115
PRA1 US 2002-431999P 20021209; DK 2002-1864 20021203
AB WO 2004050115 A UPAB: 20040716
NOVELTY - Treating or preventing (M1) "...diabetes..." or "...diabetes..." -related disease, involves administering "...exendin..." -4 compound and "...thiazolidinedione..." insulin sensitizer to the patient.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) use of "...exendin..." -4 compound and "...thiazolidinedione..." insulin sensitizer (i) for the preparation of one or more medicaments for carrying out (M1); and
(2) a pharmaceutical composition (II) comprising "...exendin..." -4 compound and "...thiazolidinedione..." preservative.

ACTIVITY - Antidiabetic; Immunosuppressive; Cytostatic; Anorectic; Antilipemic; Hypotensive; Antiarteriosclerotic; Cardiovascular-Gen.; Ophthalmological; Nephrotropic; Neuroprotective.
MECHANISM OF ACTION - Stimulator of beta -cell proliferation. No supporting data is given.

USE - (M1) is useful for treating or preventing "...diabetes..." or type 2 "...diabetes..." in adults, maturity onset "...diabetes..." , polycystic ovarian syndrome, gestational "...diabetes..." , obesity, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, hypertension, arteriosclerosis, atherosclerosis, cardiovascular disease, diabetic retinopathy, background retinopathy, proliferative retinopathy, diabetic nephropathy, neuropathy and diabetic neuropathy, where the patient is human. (M1) is useful for increasing the number of beta -cells in patient. (I) is useful for the preparation of one or more medicaments for carrying out (M1). (II) is useful for carrying out (M1) (all claimed).

Dwg. 0/0

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS ON STN
AN 1999:566077 CAPLUS
DN 131:194808
TI GLP-1 derivatives of GLP-1 and exendin with a protracted profile of action
IN Knudsen, Liselotte Bjerre; Huusfeldt, Per Olaf; Nielsen, Per Franklin;
Madsen, Kjeld
PA Novo Nordisk A/s, Den.
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 12

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9943708	A1	19990902	WO 1999-DK86	19990225
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GE, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VU, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, CA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9932477	A1	19990915	AU 1999-32477	19990225
EP 1056775	A1	20001206	EP 1999-936077	19990225
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2003522099	T2	20030722	JP 2000-333458	19990225
ZA 9901571	A	19990902	ZA 1999-1571	19990225
US 2001047084	A1	20011129	US 2001-886311	20010621
PRAI DK 1998-274	A	19980227		
US 1998-84357P	P	19980505		
WO 1999-DK86	W	19990225		
US 1999-312177	B1	19990514		

AB The present invention relates to derivs. exendin and of GLP-1(7-C), wherein C is 35 or 36, which derivs. have just one lipophilic substituent which is attached to the C-terminal amino acid residue. The derivs. have a protracted action relative to GLP-1(7-37) and are useful for treating insulin-dependent and noninsulin-dependent diabetes mellitus. The derivs. of the invention can be combined with other antidiabetics or oral hypoglycemic agents. Pharmaceutical formulations contg. the derivs. of the invention are also claimed.

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 15:45:37 ON 18 OCT 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:45:58 ON 18 OCT 2005

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:46:13 ON 18 OCT 2005
SEA EXENDIN (P) THIAZOLIDINEDIONE

1	FILE ADISINSIGHT
0*	FILE ADISNEWS
0*	FILE ANTE
0*	FILE AQUALINE
0*	FILE BIOCOMMERCE
0*	FILE BIOENG
1*	FILE BIOTECHABS
1*	FILE BIOTECHDS
1*	FILE BIOTECHNO
2	FILE CAPLUS
0*	FILE CEABA-VTB
0*	FILE CIN
196	FILE DGENE
1	FILE DRUGU
0*	FILE ESBIOBASE
0*	FILE FEDRIP
0*	FILE FOMAD
0*	FILE FOREGE
0*	FILE FROSTI
0*	FILE FSTA
4	FILE IFIPAT
0*	FILE KOSMET
0*	FILE NTIS
0*	FILE NUTRACEUT
0*	FILE PASCAL
0*	FILE PHARMAML
1	FILE TOXCENTER
0*	FILE WATER
4	FILE WPIDS
4	FILE WPINDEX

QUE EXENDIN (P) THIAZOLIDINEDIONE

SEA L1 (P) DIABETES	
1	FILE ADISINSIGHT
0*	FILE ADISNEWS
0*	FILE ANTE
0*	FILE AQUALINE
0*	FILE BIOCOMMERCE
0*	FILE BIOENG
1*	FILE BIOTECHABS
1*	FILE BIOTECHDS
1*	FILE BIOTECHNO
2	FILE CAPLUS
0*	FILE CEABA-VTB
0*	FILE CIN
196	FILE DGENE
1	FILE DRUGU
0*	FILE ESBIOBASE
0*	FILE FEDRIP
0*	FILE FOMAD

L1

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP.1569682 A2 20050907 EP 2003-775117 20031201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2004180824 A1 20040916 US 2003-726734 20031203
PRAI DK 2002-1864 A 20021203
US 2002-431999P P 20021209
WO 2003-DK824 W 20031201
AB The invention provides methods for treatment and/or prevention of
...diabetes... and ...diabetes... -related diseases. More
specifically, the methods and uses of the invention pertain to
administration of an ...exendin... -4 compd. in combination with
administration of a ...thiazolidinedione... insulin sensitizer.

=> d his

(FILE 'HOME' ENTERED AT 15:45:37 ON 18 OCT 2005)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB,
CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 15:45:58 ON 18 OCT 2005
SEA EXENDIN (P) THIAZOLIDINEDIONE

1 FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
0* FILE BIOCOMMERCE
0* FILE BIOENG
1* FILE BIOTECHABS
1* FILE BIOTECHDS
1* FILE BIOTECHNO
2 FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN
196 FILE DGENE
1 FILE DRUGU
0* FILE ESBIOBASE
0* FILE FEDRIP
0* FILE FORAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
4 FILE IFIPAT
0* FILE KOSMET
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
1 FILE TOXCENTER

0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
4 FILE IFIPAT
0* FILE KOSMET
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
0* FILE WATER
4 FILE WPIDS
4 FILE WPINDEX

QUE LI (P) DIABETES

FILE 'DGENE, IFIPAT, WPIDS, CAPLUS, ADISINSIGHT, DRUGU, BIOTECHDS,
BIOTECHNO' ENTERED AT 15:49:53 ON 18 OCT 2005

L3 210 S L2

L4 208 DUP REM L3 (2 DUPLICATES REMOVED)

L5 4 S L4 AND SYNERG?

=> s thiazolidinedione and diabetes and synerg?

L6 74 THIAZOLIDINEDIONE AND DIABETES AND SYNERG?

=> s l6 and exendin

L7 5 L6 AND EXENDIN

=> s l7 not l5

L8 1 L7 NOT L5

=> d l8 bib ab

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN

DN 2004:490736 CAPLUS

AN 141:47336

T1 Combination treatment for ...diabetes... and related diseases using

exendins and thiazolidinediones

IN Knudsen, Lotte Bjerre

PA Novo Nordisk A/S, Den.

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050115	A2	20040617	WO 2003-DK824	20031201
WO 2004050115	A3	20040722		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,			

0* FILE WATER
4 FILE WPIDS
4 FILE WPINDEX
QUE EXENDIN (P) THIAZOLIDINEDIONE

L1

SEA LI (P) DIABETES

1 FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
0* FILE BIOCOMMERCE
0* FILE BIOENG
1* FILE BIOTECHABS
1* FILE BIOTECHDS
1* FILE BIOTECHNO
2 FILE CAPIUS
0* FILE CEABA-VTB
0* FILE CIN
196 FILE DGENE
1 FILE DRUGU
0* FILE ESBIORBASE
0* FILE FEDRIP
0* FILE FONAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
4 FILE IFIPAT
0* FILE KOSMET
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML
0* FILE WATER
4 FILE WPIDS
4 FILE WPINDEX
QUE LI (P) DIABETES

L2

FILE 'DGENE, IFIPAT, WPIDS, CAPIUS, ADISINSIGHT, DRUGU, BIOTECHDS,
BIOTECHNO' ENTERED AT 15:49:53 ON 18 OCT 2005
210 S L2
L3 208 DUP REM L3 (2 DUPLICATES REMOVED)
L4 4 S L4 AND SYNERG?
L5 74 S THIAZOLIDINEDIONE AND DIABETES AND SYNERG?
L6 5 S L6 AND EXENDIN
L7 1 S L7 NOT L5
L8

=> log y			
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION	
FULL ESTIMATED COST	45.29	49.63	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION	
CA SUBSCRIBER PRICE	-1.46	-1.46	